Pulse oximetry-giant Masimo has clocked in a solid 2017 performance so far, seeing shares rise more than 38%, beginning the year at $67.40 and hitting $93.26 as of March 31.
Masimo produces a wealth of pulse oximetry and other advanced diagnostic solutions, including its Root patient monitoring and connectivity platform. The company has also delved into personal devices with its MightySat fingertip pulse oximeter.
Last month, Masimo released data from a study comparing its noninvasive SpHb measurement to conventional HbL measurements for patients undergoing liver transplantation.
Results from the trial indicated equivalence between the 2 methods, which may position the company’s equipment as a go-to for monitoring Hb during liver transplants due to the real-time results.